The cryo-EM structure of genetic CJD mutation E196K fibril reveals a novel fibril polymorph of human prion protein.
Abstract
Prion diseases are caused by the conformational conversion of prion protein (PrP). Forty-two different mutations were identified in human PrP, leading to genetic prion diseases with distinct clinical syndromes. Here, we report the cryo–electron microscopy structure of an amyloid fibril formed by full-length human PrP with E196K mutation, a genetic Creutzfeldt-Jakob disease–related mutation. This mutation disrupts key interactions in the wild-type PrP fibril, forming an amyloid fibril with a conformation distinct from the wild-type PrP fibril and hamster brain–derived prion fibril. The E196K fibril consists of two protofibrils. Each subunit forms five β strands stabilized by a disulfide bond and an unusual hydrophilic cavity stabilized by a salt bridge. Four pairs of amino acids from opposing subunits form four salt bridges to stabilize the zigzag interface of the two protofibrils. Our results provide structural evidences of the diverse prion strains and highlight the importance of familial mutations in inducing different strains.
INTRODUCTION
Prions, which mean “protein infectious agents” and convert between structurally and functionally distinct states, were originally isolated and described by S. B. Prusiner (1–3). Prion diseases are infectious, fatal neurodegenerative diseases primarily caused by the conformational conversion of prion protein (PrP) from its cellular form (PrPC) into a protease-resistant, aggregated form (PrPSc) in humans, cattle, sheep, and cervid species (1–12). Forty-two different mutations in the PrP gene (PRNP) were identified to cause a variety of genetic prion diseases, including genetic Creutzfeldt-Jakob disease (CJD), Gerstmann-Sträussler-Scheinker disease, and fatal familial insomnia (2, 4, 6, 10). These disease-related mutations can form different strains with distinct conformations and display distinct clinical syndromes with different incubation times (13–20). Most of the mutations do not cause large conformational changes in PrPC, whose structure features a folded C-terminal globular domain containing three α helices and two very short antiparallel β sheets accompanied by a largely disordered N-terminal tail (5, 10, 21). Instead, the mutations were reported to induce spontaneous generation of PrPSc in the brain of patients with genetic prion diseases (10) and in the brain of transgenic mouse models with the mutations (22, 23). Since prions were found in 1982 (1), great efforts have been dedicated to unravel the mysteries of the atomic structure of prion (7, 8, 11, 20, 24–34) and prion strains (13–20, 34). Recently, we reported a cryo–electron microscopy (cryo-EM) structure of the amyloid fibril formed by full-length wild-type human PrP featuring a parallel in-register intermolecular β sheet architecture (33), which provides structural insights into the conversion from α helix–dominant PrPC to β sheet–rich PrPSc. In addition, Kraus and co-workers reported a cryo-EM structure of a hamster brain–derived prion (263K prion) fibril featuring a hydrophobic “Greek key” motif, a middle β arch, and a disulfide β arch (34). While that work (34) is still in preprint form, it provides a richness of information directly relevant to prion strains and structural diversity, stability, and glycosylation of PrP fibrils.
The first reported patient with E196K mutation in the PRNP gene, a genetic CJD-related mutation, was a 69-year-old French woman, who died 1 year after the first recorded symptoms (35). The patients carrying this mutation have an average age at onset of 71.2 ± 5.9 years old (n = 15) (36, 37). As we note, there are more than three dozen familial mutations in PrP; most of them likely have a structural impact (2, 4, 6, 10). In this study, we focus specifically on E196K mutation because of the following reasons. First, the patients carrying E196K mutation feature rapid disease progression and short disease duration (6.6 ± 3.5 months) (36, 37), but the mechanism behind this phenomenon is unknown. Previous studies have shown that E196K mutation decreases the thermal stability of PrPC and thus increases the propensity for PrP amyloid formation (38). Second, the atomic structure of wild-type PrP fibrils has shown that several familial mutations including K194E, E196K, and E211Q may break salt bridges essential for forming the protofilament interface in wild-type PrP fibrils and thus disrupt PrP fibril structure (33), but whether genetic prion disease–related mutation E196K displays a new amyloid fibril structure is unknown.
Here, we prepared homogeneous amyloid fibrils in vitro from recombinant, full-length human E196K PrPC and determined the atomic structure by using cryo-EM. While the infectivity of these fibrils remains to be established, the structural features provide insights into the mechanism how familial mutations drive formation of different prion strains.
RESULTS
E196K forms amyloid fibrils morphologically distinct from wild-type PrP
We produced amyloid fibrils from recombinant, full-length human E196K PrPC (residues 23 to 231) overexpressed in Escherichia coli, by incubating the purified protein in 20 mM tris-HCl buffer (pH 7.4) containing 2 M guanidine hydrochloride and shaking at 37°C for 7 to 9 hours. E196K fibrils were dialyzed against NaAc buffer, purified by ultracentrifugation, resuspended in NaAc buffer, and examined by transmission electron microscopy (TEM) without further treatment.
Negative-staining TEM imaging showed that E196K PrPC formed homogeneous and unbranched fibrils (Fig. 1A), similar to wild-type PrP fibrils formed at the same conditions (Fig. 1B). The E196K fibril is composed of two protofibrils intertwined into a left-handed helix, with a fibril full width of 21.9 ± 0.7 nm and a helical pitch of 280 ± 7 nm (Fig. 1A). By comparison, the wild-type fibril is also composed of two protofibrils intertwined into a left-handed helix, but with a fibril full width of 26.3 ± 0.9 nm and a short helical pitch of 155 ± 4 nm (Fig. 1B). Thus, E196K formed an amyloid fibril with morphology distinct from wild-type PrP.
Congo red binding assays showed a red shift of the maximum absorbance, from 490 to 550 nm, in the presence of E196K fibrils (fig. S1A), which is typical of amyloid fibrils (33). This is similar to wild-type PrP fibrils formed at the same conditions (33).
Proteinase K digestion of the E196K fibrils generated a predominant band with an apparent molecular weight of 14 to 15 kDa (fig. S1C). This is different from wild-type PrP fibrils formed at the same conditions, which generated a predominant band with an apparent molecular weight of 15 to 16 kDa (33, 39, 40). Furthermore, at the same protease:PrP molar ratios, the optical density of the 14- to 15-kDa band in the E196K fibrils was remarkably weaker than that of the 15- to 16-kDa band in the wild-type fibrils (fig. S1, B and C). Bocharova and co-workers reported that proteinase K digestion of full-length wild-type mouse PrP fibrils generated a band with an apparent molecular weight of 21 kDa (41), but we and others (40) did not observe a 21-kDa band after proteinase K digestion of full-length wild-type human PrP fibrils (fig. S1B) and the E196K fibrils (fig. S1C), possibly because amyloid fibrils formed by PrPs from different mammalian species have remarkably different proteinase K–resistant features (39). In addition, we observed two other bands with apparent molecular weights of 12 and 10 kDa after proteinase K digestion of the E196K fibrils (fig. S1C), which is similar to wild-type PrP fibrils (fig. S1B). Together, the data showed that the E196K fibril exhibits a distinct morphology with weaker protease resistance activity compared to the wild-type fibril.
Cryo-EM structure of E196K fibrils
We determined the atomic structure of the E196K amyloid fibrils by cryo-EM (Table 1). The cryo-EM micrographs and two-dimensional (2D) class average images show that the E196K fibril is composed of two protofibrils intertwined into a left-handed helix (Fig. 1C and fig. S2A), with a helical pitch longer than the wild-type fibril (Fig. 1, C and D). Furthermore, two protofilaments in each E196K fibril is arranged in a staggered manner (fig. S2, B and C), similar to wild-type PrP fibrils formed at the same conditions (33). The fibrils are morphologically homogeneous, showing a fibril full width of 21.4 ± 0.7 nm (Fig. 1C and fig. S2A). This is narrower than wild-type PrP fibrils (33) but similar in size to previously described ex vivo, infectious PrPSc fibrils, which showed a width of ~20 nm based on negative staining on TEM (31, 42).
Table 1. Cryo-EM data collection, refinement, and validation statistics.
E196K fibril (EMD-30887, PDB 7DWV) | |
Data collection and processing | |
Magnification | 29,000 |
Voltage (kV) | 300 |
Camera | K2 summit (Titan Krios) |
Frame exposure time (s) | 0.2 |
Movie frames (n) | 40 |
Electron exposure (e−/Å2) | 64 |
Defocus range (μm) | −3.0 to −1.5 |
Pixel size (Å) | 1.014 |
Symmetry imposed | C1 |
Box size (pixel) | 400 |
Interbox distance (Å) | 40.6 |
Micrographs collected (n) | 4883 |
Segments extracted (n) | 619,926 |
Segments after Class2D (n) | 560,963 |
Segments after Class3D (n) | 24,083 |
Map resolution (Å) | 3.07 |
FSC threshold | 0.143 |
Map resolution range (Å) | 2.20–4.01 |
Refinement | |
Initial model used | 6LNI |
Model resolution (Å) | 3.07 |
FSC threshold | 0.143 |
Model resolution range (Å) | 3.07 |
Map sharpening B factor (Å2) | −43.26 |
Model composition | |
Nonhydrogen atoms | 2064 |
Protein residues | 258 |
Ligands | 0 |
B factors (Å2) | |
Protein | 101.56 |
R.m.s. deviations | |
Bond lengths (Å) | 0.007 |
Bond angles (°) | 0.795 |
Validation | |
MolProbity score | 2.54 |
Clashscore | 16.67 |
Poor rotamers (%) | 0 |
Ramachandran plot | |
Favored (%) | 73.17 |
Allowed (%) | 26.83 |
Disallowed (%) | 0 |
Using helical reconstruction in RELION3.1 (43), we determined a density map of the ordered core of E196K fibrils, with an overall resolution of 3.07 Å, which features well-resolved side-chain densities and clearly separated β strands along the helical axis (Fig. 1E and fig. S3). The 3D map showed two protofibrils in the E196K fibril intertwined into a left-handed helix, with a half-helical pitch of 126.4 nm (Fig. 2A), which is remarkably longer than that of the wild-type fibril (33). The width of the fibril core is ~11 nm (Fig. 2A). This is narrower than wild-type PrP fibrils formed at the same conditions (33) but similar in size to previously described ex vivo, infectious PrPSc fibrils, which showed a width of ~10 nm based on cryo-EM images (28). The wild-type fibril full width in Fig. 1 (B and D) was 26.3 ± 0.9 and 26.8 ± 1.2 nm, respectively. This is remarkably wider than the wild-type fibril core width of ~14 nm (33), possibly because residues 23 to 169 for the wild-type fibril were not modeled in the cryo-EM density (33). Cross-sectional view of the 3D map of the E196K fibril (Fig. 1E) shows two protofibrils conformationally distinct from those of the wild-type PrP fibril (Fig. 1F). The protofilaments in the E196K fibril form a dimer with a screw symmetry of approximately 21 (Fig. 2, B to D). The subunits in each E196K protofibril stack along the fibril axis with a helical rise of 4.82 Å and twist of −0.68° (Fig. 2E), and the subunits in two protofibrils stack along the fibril axis with a helical rise of 2.41 Å (Fig. 2F).
We unambiguously built an E196K fibril model comprising residues 175 to 217 at 3.07 Å (Fig. 3) and an unmasked E196K fibril model comprising residues 171 to 222 at 3.59 Å (fig. S4), both of which are slightly shorter than the wild-type PrP fibril core comprising residues 170 to 229 (33). Side-chain densities for most residues in the E196K fibril core had high local resolution (2.20 to 3.28 Å) (Fig. 3, A and B, and fig. S4, A to C). The exterior of the E196K fibril core is mostly hydrophilic. The fibril core is stabilized by an intramolecular disulfide bond between Cys179 and Cys214 (Fig. 3, A and B, and figs. S4, B and C, and S5, A and B) (also present in both PrPC and PrPSc) (24, 27, 28, 30) and a hydrogen bond between His177 and Thr216 (fig. S5, A and B) in each monomer. In sharp comparison to the highly hydrophobic cavity observed in the wild-type fibril, the E196K fibril core is composed of an unusual hydrophilic cavity in each subunit (Fig. 3, B and G, and fig. S4C), which may decrease the fibril stability of E196K. Lys185 and Asp202 from the same subunit form a salt bridge, and His187 and Asp202 from the adjacent subunit form another salt bridge to stabilize the hydrophilic cavity (fig. S6, A to C).
We observed two unidentified densities flanking the two protofibrils in the E196K fibril, termed two islands (Fig. 3A and fig. S4), which are reminiscent of those islands observed in the structures of filaments formed by α-synuclein hereditary disease mutant H50Q (44). Each island, probably comprising residues 136 to 142 from E196K and forming a β strand (β0), is located on the opposing side of hydrophobic side chains of Val180, Ile182, and Ile184 in each monomer (fig. S4, B to D). The side chains of Val180, Ile182, Ile184, Pro137, Ile139, and Phe141 form a hydrophobic steric zipper-like interface, thereby stabilizing the E196K fibrils. The presence of two islands represents one of the major structural differences between E196K and wild-type fibrils.
Five β strands (β1 to β5) and six β strands (β0 to β5) are present in the E196K fibril core structure at 3.07 Å (Fig. 3, B to D) and an unmasked structure at 3.59 Å (fig. S4C), respectively. The E196K fibril core features a compact fold containing a long β strand (β1) and four short β strands (β2 to β5). This is different from a previously observed wild-type PrP fibril core, which contains six short β strands (β1 to β6) (33). The height of one layer of the subunit along the helical axis is 7.24 Å (Fig. 3E). A U-turn between β1 and β2 containing residues 193TKGKN197 enables antiparallel cross-β packing of the first part of β1 against β2 and a disulfide bond between Cys179 in β1, and Cys214 in β5 enables antiparallel cross-β packing of the last part of β1 against β5 (Fig. 3, B and D, and fig. S4C).
In the E196K fibril, two pairs of amino acids (Lys194 and Glu207; Lys196 and Glu200) from opposing subunits form four salt bridges at the zigzag interface of the two protofibrils (Figs. 2C and 3, A, B, F, and G, and fig. S4, B and C). The interfaces in the E196K fibril feature mixed compositions of hydrophilic and hydrophobic side chains (Fig. 3, B and G, and fig. S4C). They are reminiscent of those interfaces observed in the structures of Tau filaments extracted from the brains of patients with corticobasal degeneration (45) and amyloid fibrils formed by the S20G mutation in human amylin (46). In the wild-type PrP fibril, however, Lys194 and Glu196 from opposing subunits form two salt bridges that create a hydrophilic cavity at the interface of the two protofibrils with two additional unidentified densities (33).
We then compare protofilament interfaces of E196K and wild-type fibrils in detail (Fig. 4). The E196K fibril has a long interface comprising residues 194 to 208, but the wild-type fibril features a very short interface comprising only three residues 194 to 196 (Fig. 4A). Four pairs of strong intermolecular salt bridges formed by Glu207 and Lys194 and Glu200 and Lys196 (with distances less than 4 Å; Fig. 4, B to E) and two pairs of weak salt bridges formed by Glu207 and Arg208 from the same subunit (with a distance of 6.3 Å; Figs. 3B and 4, B to E) are identified in the zigzag interface between E196K protofibrils. In contrast, two strong intermolecular salt bridges between Lys194 and Glu196 are formed at the dimer interface between wild-type PrP protofibrils (with distances less than 4 Å; Fig. 4, F and G). Thus, the E196K mutation disrupts the key salt bridges in wild-type PrP fibrils and results in a rearrangement of the overall structure, forming an amyloid fibril with a conformation distinct from the wild-type fibril (Figs. 4 and 5 and fig. S5).
The E196K mutation significantly decreases the conformational stability of PrP fibrils
Compared to the wild-type fibril, the E196K fibril features a smaller and distinct fibril core with an unusual hydrophilic cavity in the center. We next examined whether the E196K fibril exhibits distinct conformational stability from the wild-type fibril. Chemical and/or thermal denaturation was widely used to evaluate the conformational stability of proteinase-resistant PrP fibrils (19, 47, 48). A strong chaotropic salt, guanidine thiocyanate, was used in our denaturation assay (fig. S7A). The C1/2 value of the wild-type PrP fibril is 2.00 ± 0.03 M (fig. S7B), which is consistent with previous data (47). Notably, the C1/2 value of the E196K fibril is 1.54 ± 0.06 M (fig. S7B), which is significantly lower than the wild-type fibril, suggesting that the E196K fibril is less stable than the wild type. The lability of E196K fibrils was confirmed by our salt gradient experiments (fig. S8A). Intriguingly, the C1/2 value of the E196K fibril in the presence of 150 mM or 1 M NaCl is 1.53 ± 0.06 M (fig. S8B) or 1.77 ± 0.10 M (fig. S8C), which is significantly lower than that of the wild-type fibril in the presence of 150 mM (2.00 ± 0.05 M; fig. S8B) or 1 M salt (2.47 ± 0.13 M; fig. S8C), suggesting that the E196K fibril is less stable than the wild type at physiological ionic strength and high salt concentration.
To validate the stability differences between E196K and wild-type fibrils, we further measured their thermostabilities. The PrP fibrils were incubated with 6% SDS under a thermal gradient from 25 to 100°C, and the soluble PrP disassembled from fibrils was measured by SDS–polyacrylamide gel electrophoresis (SDS-PAGE) (fig. S7, C and D). To determine the melting temperature (Tm), we normalized the amount of soluble PrP monomers as a ratio of the density of soluble PrP monomer band at each temperature over the density of soluble PrP monomer band at 100°C and presented thermal stability data in the form of a plot (normalized amount of soluble PrP monomers versus temperature) (fig. S7E). The results showed that the Tm value of E196K fibrils is ~75°C, substantially lower than that of the wild-type fibrils (~95°C) (fig. S7E). Together, these results demonstrate that the E196K fibril has a significantly lower conformational stability compared to the wild-type fibril.
However, it is not fully obvious why the structure of the sequence variant would induce greater fibril lability. While E196K fibrils exhibit a presumably hydrated cavity at their center (Fig. 3, B and G, and figs. S4C and S6, A to C), they also contain charge-paired interactions (Figs. 3, B and F, and 4, B to E, and figs. S4C and S6, A to C) and bury some hydrophobic residues (Fig. 3, B and G, and fig. S4, B to D). If polar interactions facilitate meaningful, on-pathway contacts, then one might predict that salt-mediated screening of charges would influence the lability of fibrils and perhaps even the rates of fibril formation. To test this prediction, we performed salt gradient experiments (figs. S8A and S9, A and B). We unexpectedly found that 1 M NaCl, which screens charge-charge interactions in proteins, significantly increased the conformational stability of wild-type PrP fibrils (P = 0.00035; fig. S8D) but did not significantly influence the lability of E196K fibrils (P = 0.0058; fig. S8D). The lag time of E196K fibril formation in the presence of 1 M NaCl is 7.46 ± 1.41 hours (fig. S9D), which is significantly higher than that in the absence of salt (2.00 ± 0.68 hours, P = 0.0038; fig. S9D), but the lag time of fibril formation of wild-type PrP in the presence of 1 M NaCl is 5.88 ± 1.07 hours (fig. S9C), which is not significantly higher than that in the absence of salt (2.96 ± 0.38 hours, P = 0.011; fig. S9C), suggesting that 1 M salt significantly slowed down fibril formation of E196K but not wild-type PrP. Collectively, these results reveal that high salt concentration differently influences the lability of wild-type and E196K fibrils and the fibrillization kinetics of wild-type and E196K PrPs. It is possible that the differences observed in the melting assay (fig. S7, C to E) are more reflective of the type of interactions holding the cores of the wild-type and E196K fibrils, hydrophobic versus ionic, respectively. The polar contacts holding the E196K fibril together (Figs. 3, B and F, and 4, B to E, and figs. S4C and S6) are intriguing and could potentially inform on the types of structural differences across in vivo structures formed by wild-type or sequence variant PrPs.
DISCUSSION
We compared the structures of PrPC, the E196K fibril, the wild-type PrP fibril, and the 263K prion fibril (Fig. 5). Notably, the PrP molecule adopts largely distinctive secondary structures in four different PrP structures, highlighting the high structural polymorphs and diversity of PrP in soluble and fibrillar forms. The human PrPC contains three α helices, two very short antiparallel β sheets, and a single disulfide bond between Cys179 in α2 and Cys214 in α3 (5, 10, 21) (Fig. 5A). Once it folds into its fibrillar form, the PrP subunit undergoes a totally conformational rearrangement. The wild-type human PrP fibril core contains six short β sheets (β1 to β6), a very short interface comprising only three residues 194 to 196, and one disulfide bond between Cys179 in a loop (linking β1 to β2) and Cys214 in β5 (33) (Fig. 5, A and B). In contrast, the E196K fibril core contains a long β sheet (β1), four short β sheets (β2-β5), a long interface comprising residues 194 to 208, and one disulfide bond between Cys179 in β1 and Cys214 in β5 (Fig. 5, A and C), with a higher β sheet content (77%) than in the wild-type fibril core (55%) (Fig. 5, A to C). The E196K mutation disrupts important interactions in PrP fibrils and results in a rearrangement of the overall structure, forming an amyloid fibril with a dimer interface and a conformation distinct from the wild-type fibril (Fig. 5, B to D). The hamster brain–derived prion (263K prion) fibril core consists of a single protofilament, which contains 11 short β strands (β1 to β11) and one disulfide bond between Cys179 in a loop (linking β7 to β8) and Cys214 in a long loop (linking β10 to β11) (Fig. 5, A and E) (34). The structure of the 263K prion fibril (34) is partly compatible with the structures of the wild-type PrP fibril (33) and the E196K fibril (this work), where β1, β2, β3, and β6 in the wild-type PrP fibril and β3 in the E196K fibril would correspond to β7, β8, β9, β11, and β10 in the 263K prion fibril core, respectively; in all three models, the fibril features a parallel in-register intermolecular β sheet architecture (Fig. 5, A to C, and E). The three different fibril structures revealed the following key structural differences among the 263K prion fibril, the E196K fibril, and the wild-type fibril. First, the signature of this infectious prion is much higher resistance to proteolytic digestion and substantially longer proteinase K–resistant core compared with PrP fibrils formed in vitro (starting at residue ~95 in contrast to 175 for the E196K fibril and 170 for the wild-type fibril) (Fig. 5, B to E). Second, the number of protofilaments is one for the 263K prion fibril but two for both the E196K fibril and the wild-type PrP fibril (Fig. 5, B to G). Third, the overall folding motif even within the overlapping C-terminal segment of the core of the 263K prion fibril is different from those of E196K and wild-type fibrils. The disulfide β arch in 263K prion contains two N-linked glycans (34), but our recombinant PrP fibrils are nonglycosylated [(33), this work]. The flanks of the disulfide β arches in the 263K prion fibril (34) and the E196K fibril are straighter than that in the wild-type PrP fibril [Fig. 5, B to E, and Extended Data figure 6 in (34)]. Fourth, both the 263K prion fibril core (34) and the E196K fibril core contain two hydrophilic cavities (Fig. 3, F and G), but the wild-type PrP fibril core contains two hydrophobic cavities (33). Last, most of the antibody epitopes and proteolytic cleavage sites lie on the 263K prion fibril core structure [Extended Data figure 7 in (34)] but do not lie on core structures of E196K and wild-type fibrils. These results provide structural evidence that different prion strains have distinct conformations, which may underscore a pivotal role of the specific structural features in driving the disease phenotype. The question of what distinguishes infectious ex vivo fibrils from recombinantly generated forms remains an important and open one.
Conformational stabilities of PrPSc and PrP fibrils assessed by measuring their resistance to chemical and/or thermal denaturation are used to probe the structural differences between prion strains (13, 16, 19, 20, 47, 48). However, the structural basis of the stability differences between different strains remains to be established (19, 20, 47, 48). We previously determined a high-resolution cryo-EM structure of an amyloid fibril formed by full-length wild-type human PrP (33). The present study expands these studies, reporting the cryo-EM structure of an amyloid fibril generated from human PrP with the E196K mutation (which corresponds to one of the mutations associated with genetic prion diseases). In that sense, this follow-up study probes the impact of disease-associated sequence variants on the original PrP amyloid fibril structure. In this case, the charge-flipping mutation of Glu to Lys at position 196 disrupts key interactions in the wild-type fibril structure and induces a rearrangement of its core. Our structure data revealed the key structural differences between E196K and wild-type fibrils, including (i) hydrophilic cavity versus hydrophobic cavity; (ii) a mixed hydrophilic and hydrophobic protofibril interface versus a short hydrophilic protofibril interface (the nature of the interface between two protofilaments); and (iii) five versus six β strands in the core. This may help to understand how a single point mutation may lead to formation of a novel structure of a prion fibril with largely distinct properties. It should be mentioned that prion strains are defined by bona fide infectious isolates (which may nonetheless result from different structures) and that a single point mutation may lead to formation of a new prion strain with largely distinct properties (13–20).
Guest and colleagues reported that three weak salt bridges formed by His187 and Asp202, Glu196 and Asp202, and Arg164 and Asp178, with a distance of 8.0, 7.9, and 6.0 Å, respectively, and a strong salt bridge formed by Arg208 and Glu211 with a distance of 2.6 Å in the human PrPC were important according to the results of analysis of theoretical mathematics or model mathematics with nuclear magnetic resonance (49). Here, a strong salt bridge is defined as an interaction between two groups of opposite charges in which at least one pair of heavy atoms is within distance less than 4 Å (50). We previously reported that two pairs of amino acids (Lys194 and Glu196 and Glu196 and Lys194) from opposing subunits of the wild-type human PrP fibril formed two strong intermolecular salt bridges, with a distance of 2.2 and 3.1 Å, respectively, to stabilize the short hydrophilic protofibril interface (33). We also reported that for the wild-type fibril, two pairs of strong salt bridges formed by Glu211 and Arg228 from the same subunit, with a distance of 3.2 Å; two pairs of salt bridges formed by Asp202 and Lys204 from the same subunit, with a distance of 4.3 Å; and eight pairs of weak salt bridges formed by Lys204 and Glu207, Glu207 and Arg208, Arg208 and Glu211, and Arg220 and Glu211 also from the same subunit, with a distance of 5.0, 5.9, 7.0, and 5.3 Å, respectively, were important according to a high-resolution cryo-EM structure (33). Here, we reported a new cryo-EM structure of a PrP amyloid fibril, whose sequence encodes a disease-related sequence variant: E196K. Four pairs of amino acids (Lys194 and Glu207; Lys196 and Glu200; Glu200 and Lys196; and Glu207 and Lys194) from opposing subunits of the E196K fibril formed four strong intermolecular salt bridges, with a distance of 3.1, 3.4, 3.4, and 3.0 Å, respectively, and Glu207 and Arg208 from the same subunit of the E196K fibril formed two weak salt bridges, with a distance of 6.3 Å, to stabilize the mixed hydrophilic and hydrophobic protofibril interface. Lys185 and Asp202 from the same subunit of the E196K fibril formed two strong salt bridges, and His187 and Asp202 from the adjacent subunit of the E196K fibril formed two salt bridges to stabilize the two hydrophilic cavities.
Asn181 and Asn197 were previously reported to be glycosylated in wild-type PrPSc (24, 27, 30). The recombinant PrPs we used are nonglycosylated. However, in our wild-type PrP fibril model, the side chains of the two Asn residues appear well exposed to solvent (33) and thus are able to sterically accommodate bulky, N-linked glycans, as shown by recent molecular dynamics simulations (51, 52). Intriguingly, in the E196K fibril structure, the side chains of Asn181 and Asn197 are buried in the interior of a hydrophilic core (Fig. 3, A and B). Notably, the side chain of Asn181 in the E196K fibril fold appears well exposed to an open area of the hydrophilic core (Fig. 3, A and B) and should thus be able to accommodate a bulky, N-linked glycan. The side chain of Asn197, however, appears exposed to a quite crowded area of the hydrophilic core (Fig. 3, A and B) and probably does not have enough space to accommodate a bulky, N-linked glycan. Thus, our E196K fibril model would represent the fibril core of monoglycosylated PrPSc. Very recently, mono-glycosylated PrPSc has been found to have structural instability (53) and form fibrillar plaques (54) in some PrP mutations, including genetic CJD-related mutations V180I and T183A (54).
In summary, genetic prion disease–related mutation E196K displays a novel amyloid fibril structure revealed by cryo-EM and has a significantly lower conformational stability and protease resistance activity compared to the wild-type fibril. The reported cryo-EM structure of the E196K PrP fibril reveals an unusual overall structure when compared to the wild-type fibril, characterized by a disruption of key salt bridges, a hydrophilic cavity, two unidentified densities flanking the protofibrils, and five instead of six β strands in the core. The structure provides structural evidence for different prion strains and may inspire future research on the mechanism how the familial mutants of PrP can drive disease, given the issue of structural diversity among amyloid fibrils.
MATERIALS AND METHODS
Protein expression and purification
A plasmid-encoding, full-length human PrP (23-231) was a gift from G.-F. Xiao (Wuhan Institute of Virology, Chinese Academy of Sciences). The gene for PrP 23-231 was constructed in the vector pET-30a (+), and a PrP mutant E196K was constructed by site-directed mutagenesis using a wild-type PrP template; the primers are shown in table S1. All PrP plasmids were transformed into E. coli. Recombinant full-length wild-type human PrP and its variant E196K were expressed from the vector pET-30a (+) in E. coli BL21 (DE3) cells (Novagen, Merck, Darmstadt, Germany). PrP proteins were purified by high-performance liquid chromatography on a C4 reverse-phase column (Shimadzu, Kyoto, Japan) as described by Bocharova et al. (41) and Zhou et al. (39). After purification, recombinant wild-type PrPC and E196K PrPC were dialyzed against 20 mM tris-HCl buffer (pH 7.4) three times, concentrated, filtered, and stored at −80°C. SDS-PAGE and mass spectrometry were used to confirm that the purified human PrP proteins were single species with an intact disulfide bond. We used a NanoDrop OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific) to determine the concentrations of wild-type human PrPC and E196K PrPC, using their absorbances at 280 nm and the molar extinction coefficients calculated from the composition of the proteins (http://web.expasy.org/protparam/).
PrP fibril formation
Full-length recombinant wild-type human PrPC and E196K PrPC (40 μM) were incubated in 20 mM tris-HCl buffer (pH 7.4) containing 2 M guanidine hydrochloride (GdnHCl) with shaking at 180 rpm at 37°C for 9 to 11 and 7 to 9 hours, respectively, and the wild-type and E196K fibrils were collected. Large aggregates in E196K fibril samples and the wild-type fibril samples were removed by centrifugation for 5000g at 4°C for 10 min. The supernatants were then dialyzed against 20 mM NaAc buffer (pH 5.0) three times to ensure that GdnHCl had been removed. After dialysis, E196K fibril samples and the wild-type fibril samples were purified by ultracentrifugation for 100,000g for 30 min twice and washed with 20 mM NaAc buffer (pH 5.0). The pellets containing E196K fibrils or the wild-type fibrils were resuspended in 100 μl of 20 mM NaAc buffer (pH 5.0) and not treated with proteinase K. We used a NanoDrop OneC Microvolume UV-Vis Spectrophotometer (Thermo Fisher Scientific) to determine the concentrations of the E196K fibril and the wild-type PrP fibril using their absorbances at 280 nm and the molar extinction coefficients calculated from the composition of PrPs (http://web.expasy.org/protparam/).
Congo red binding assays
E196K fibrils were analyzed by Congo red binding assays. A stock solution of 200 μM Congo red was prepared in phosphate-buffered saline and filtered through a filter of 0.22-μm pore size before use. In a typical assay, the E196K fibril sample was mixed with a solution of Congo red to yield a final Congo red concentration of 50 μM and a final PrP concentration of 10 μM, and the absorbance spectrum between 400 and 700 nm was then recorded on a Cytation 3 Cell Imaging Multi-Mode Reader (BioTek).
TEM of E196K fibrils
E196K fibrils were examined by TEM of negatively stained samples. Ten microliters of E196K fibril samples (~13 μM) were loaded on copper grids for 30 s and washed with H2O for 10 s. Samples on grids were then stained with 2% (w/v) uranyl acetate for 30 s and dried in air at 25°C. The stained samples were examined using a JEM-1400 Plus transmission electron microscope (JEOL) operating at 100 kV.
Proteinase K digestion assay
E196K fibrils were assessed by proteinase K digestion. The E196K fibril samples were incubated with proteinase K at a protease:PrP molar ratio of 1:500 to 1:100 for 1 hour at 37°C. Digestion was stopped by the addition of 2 mM phenylmethylsulfonyl fluoride, and the samples were analyzed in 15% SDS-PAGE and detected by silver staining.
Cryo-EM of PrP fibrils
E196K fibrils were produced as described above. An aliquot of 3.5 μl of ~13 μM E196K fibril solution was applied to glow-discharged holey carbon grids (Quantifoil Cu R1.2/1.3, 300 mesh), blotted for 3.5 s and plunge-frozen in liquid ethane using an FEI Vitrobot Mark IV. The grids were examined using an FEI Talos F200C microscope, operated at 200 kV, and equipped with a field emission gun and an FEI Ceta camera (Thermo Fisher Scientific). The cryo-EM micrographs were acquired on an FEI Titan Krios microscope operated at 300 kV (Thermo Fisher Scientific) and equipped with a Gatan K2 Summit camera. A total of 4883 movies were collected in counting mode at a nominal magnification of ×29,000 (pixel size, 1.014 Å) and a dose of 8 e− Å−2 s−1 (see Table 1). An exposure time of 8 s was used, and the resulting videos were dose-fractionated into 40 frames. A defocus range of −1.5 to −3.0 μm was used.
Helical reconstruction
All 40 video frames were aligned, summed, and dose-weighted by MotionCor2 and further binned to a pixel size of 1.014 Å (55). Contrast transfer function estimation of aligned, dose-weighted micrographs was performed by CTFFIND4.1.8 (56). Subsequent image-processing steps, which include manual picking, particle extraction, 2D and 3D classifications, 3D refinement, and postprocessing, were performed by RELION3.1 (43).
In total, 25,301 fibrils were picked manually from 4883 micrographs, and 686- and 400-pixel boxes were used to extract particles by 90% overlap scheme. Two-dimensional classification of 686-box size particles was used to calculate the initial twist angle. In regard to helical rise, 4.8 Å was used as the initial value. Particles were extracted into 400-box sizes for further processing. After several iterations of 2D and 3D classifications, particles with the same morphology were picked out. Local searches of symmetry in 3D classification were used to determine the final twist angle and rise value. The 3D initial model was built by selected 2D classes; 3D classification was performed several times to generate a proper reference map for 3D refinement. Three-dimensional refinement of the selected 3D classes with appropriate reference was performed to obtain final reconstruction. The final map of E196K fibrils was convergent with a rise of 2.41 Å and a twist angle of 179.66°. Postprocessing was preformed to sharpen the map with a B factor of −43.26 Å2. On the basis of the gold standard Fourier shell correlation (FSC) = 0.143 criteria, the overall resolution was reported as 3.07 Å. The statistics of cryo-EM data collection and refinement is shown in Table 1.
Atomic model building and refinement
COOT (57) was used to build and modify the atomic model of the E196K fibril on the basis of the cryo-EM structure of the wild-type PrP fibril [Protein Data Bank (PDB) 6LNI] (33). The model with three adjacent layers was generated for structure refinement. The model was refined using the real-space refinement program in PHENIX (58).
Global denaturation of E196K and wild-type fibrils analyzed by ThT fluorescence and SDS-PAGE
Amyloid fibrils were produced from wild-type and E196K PrPs incubated in 20 mM tris-HCl buffer (pH 7.4) containing 2 M guanidine hydrochloride and shaking at 37°C for 10 hours. Samples (40 μM) of the PrP fibrils were incubated for 1 hour at 25°C in the presence of different concentrations of guanidine thiocyanate (GdnSCN) and 0, 150 mM, or 1 M NaCl. The concentration of GdnSCN was then adjusted to 0.35 M, followed by a thioflavin T (ThT) binding assay. A Cytation 3 Cell Imaging Multi-Mode Reader (BioTek) was used to the ThT fluorescence produced, with excitation at 450 nm and emission at 480 nm. The half-concentration at which the ThT fluorescence intensity of PrP fibrils is decreased by 50% (C1/2) of the E196K fibril and the wild-type fibril was determined using a sigmoidal equation (59, 60) using the above ThT fluorescence data. Statistical analyses were performed using the revised Student’s t test. Values of P < 0.005 indicate statistically significant differences. The following notation is used throughout: *P < 0.005, **P < 0.001, and ***P < 0.0001 relative to control. Samples (40 μM) of the PrP fibrils were also dialyzed against 20 mM NaAc buffer (pH 5.0) for three times and diluted to a final concentration of 16 μM using 10% SDS. The final concentration SDS was 6%. The PrP fibrils were incubated with 6% SDS for 5 min under a thermal gradient from 25 to 100°C, mixed with the 5× loading buffer (without SDS, β-mercaptoethanol, and heating) and separated by 12.5% SDS-PAGE. The soluble PrP monomers were detected by SDS-PAGE with Coomassie Blue R250 staining. The normalized amount of soluble PrP monomers was determined as a ratio of the density of soluble PrP monomer band at each temperature over the density of soluble PrP monomer band at 100°C.
Fibrillization kinetics of wild-type PrP and its variant E196K analyzed by ThT fluorescence
Samples (20 μM) of wild-type and E196K PrPs were incubated in 20 mM tris-HCl buffer (pH 7.4) containing 2 M guanidine hydrochloride and shaking at 180 rpm and 37°C for 13 hours in the absence or presence of 50, 150, 300, and 500 mM or 1 M NaCl, and analyzed by a ThT binding assay. The final concentrations of PrP and ThT were 1 and 125 μM, respectively. A Cytation 3 Cell Imaging Multi-Mode Reader (BioTek) was used to the ThT fluorescence produced, with excitation at 450 nm and emission at 480 nm. The lag times of fibril formation of wild-type and E196K PrPs in the presence of different concentrations of salt were determined using a sigmoidal equation (59, 60) using the above ThT fluorescence data. Statistical analyses were performed using the revised Student’s t test. Values of P < 0.005 indicate statistically significant differences. The following notation is used throughout: *P < 0.005, **P < 0.001, and ***P < 0.0001 relative to control.
Acknowledgments
Cryo-EM data were collected at the Center of Cryo Electron Microscopy, Zhejiang University, China. We thank G.-F. Xiao (Wuhan Institute of Virology, Chinese Academy of Sciences) for the gift of the human PrPC plasmid; S. Chang (Center of Cryo Electron Microscopy, Zhejiang University), L. Wu (Center of Cryo Electron Microscopy, Zhejiang University), and X. Zhang (Zhejiang University School of Medicine) for technical assistance with cryo-EM; and Y. Wang (Institute of Biophysics, Chinese Academy of Sciences) for helpful suggestions. Funding: Y.L. was supported by the National Natural Science Foundation of China (32071212), and C.L. was supported by the Major State Basic Research Development Program (2016YFA0501902). Y.L. was also supported by the National Natural Science Foundation of China (31770833 and 31570779), the Translational Medicine and Interdisciplinary Research Joint Fund of Zhongnan Hospital of Wuhan University (ZNJC201934), and the Fundamental Research Fund for the Central Universities of China (2015204020201). C.L. was also supported by the National Natural Science Foundation of China (91853113), the Science and Technology Commission of Shanghai Municipality (18JC1420500), and Shanghai Municipal Science and Technology Major Project (2019SHZDZX02). P.Y. was supported by the Major State Basic Research Development Program (2018YFA0507700) and the National Natural Science Foundation of China (31722017). Author contributions: P.Y., C.L., and Y.L. supervised the project. L.-Q.W., C.L., and Y.L. designed the experiments. L.-Q.W., H.-Y.Y., X.-N.L., and J.C. purified the E196K PrPC and E196K fibrils. L.-Q.W., H.-Y.Y., and H.-B.D. performed Congo red binding, ThT binding, proteinase K digestion, and conformational stability assays of PrP fibrils. L.-Q.W., K.Z., H.-Y.Y., Y.M., Q.W., C.W., Y.S., D.Z., and D.L. collected, processed, and/or analyzed cryo-EM data. L.-Q.W., K.Z., C.L., and Y.L. wrote the manuscript. All authors proofread and approved the manuscript. Competing interests: The authors declare that they have no competing interests. Data and materials availability: All data needed to evaluate the conclusions in the paper are present in the paper and/or the Supplementary Materials. Cryo-EM density maps and the atomic model of human E196K PrP fibrils are available through the Electron Microscopy Data Bank and PDB with accession codes EMD-30887 and PDB 7DWV, respectively.
Supplementary Materials
This PDF file includes:
REFERENCES AND NOTES
- 1.Prusiner S. B., Novel proteinaceous infectious particles cause scrapie. Science 216, 136–144 (1982). [DOI] [PubMed] [Google Scholar]
- 2.Prusiner S. B., Prions. Proc. Natl. Acad. Sci. U.S.A. 95, 13363–13383 (1998). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Prusiner S. B., Molecular biology and pathogenesis of prion diseases. Trends Biochem. Sci. 21, 482–487 (1996). [DOI] [PubMed] [Google Scholar]
- 4.Scheckel C., Aguzzi A., Prions, prionoids and protein misfolding disorders. Nat. Rev. Genet. 19, 405–418 (2018). [DOI] [PubMed] [Google Scholar]
- 5.Watts J. C., Bourkas M. E. C., Arshad H., The function of the cellular prion protein in health and disease. Acta Neuropathol. 135, 159–178 (2018). [DOI] [PubMed] [Google Scholar]
- 6.Kim M.-O., Takada L. T., Wong K., Forner S. A., Geschwind M. D., Genetic PrP prion diseases. Cold Spring Harb. Perspect. Biol. 10, a033134 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Pan K. M., Baldwin M., Nguyen J., Gasset M., Serban A., Groth D., Mehlhorn I., Huang Z., Fletterick R. J., Cohen F. E., Prusiner S. B., Conversion of α-helices into β-sheets features in the formation of the scrapie prion proteins. Proc. Natl. Acad. Sci. U.S.A. 90, 10962–10966 (1993). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Soto C., Prion hypothesis: The end of the controversy? Trends Biochem. Sci. 36, 151–158 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Prusiner S. B., A unifying role for prions in neurodegenerative diseases. Science 336, 1511–1513 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Rossetti G., Cong X., Caliandro R., Legname G., Carloni P., Common structural traits across pathogenic mutants of the human prion protein and their implications for familial prion diseases. J. Mol. Biol. 411, 700–712 (2011). [DOI] [PubMed] [Google Scholar]
- 11.Diaz-Espinoza R., Soto C., High-resolution structure of infectious prion protein: The final frontier. Nat. Struct. Mol. Biol. 19, 370–377 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Soto C., Estrada L., Castilla J., Amyloids, prions and the inherent infectious nature of misfolded protein aggregates. Trends Biochem. Sci. 31, 150–155 (2006). [DOI] [PubMed] [Google Scholar]
- 13.Colby D. W., Giles K., Legname G., Wille H., Baskakov I. V., DeArmond S. J., Prusiner S. B., Design and construction of diverse mammalian prion strains. Proc. Natl. Acad. Sci. U.S.A. 106, 20417–20422 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Safar J., Wille H., Itri V., Groth D., Serban H., Torchia M., Cohen F. E., Prusiner S. B., Eight prion strains have PrPSc molecules with different conformations. Nat. Med. 4, 1157–1165 (1998). [DOI] [PubMed] [Google Scholar]
- 15.Caughey B., Raymond G. J., Bessen R. A., Strain-dependent differences in β-sheet conformations of abnormal prion protein. J. Biol. Chem. 273, 32230–32235 (1998). [DOI] [PubMed] [Google Scholar]
- 16.Peretz D., Williamson R. A., Legname G., Matsunaga Y., Vergara J., Burton D. R., DeArmond S. J., Prusiner S. B., Scott M. R., A change in the conformation of prions accompanies the emergence of a new prion strain. Neuron 34, 921–932 (2002). [DOI] [PubMed] [Google Scholar]
- 17.Aguzzi A., Heikenwalder M., Polymenidou M., Insights into prion strains and neurotoxicity. Nat. Rev. Mol. Cell Biol. 8, 552–561 (2007). [DOI] [PubMed] [Google Scholar]
- 18.Collinge J., Clarke A. R., A general model of prion strains and their pathogenicity. Science 318, 930–936 (2007). [DOI] [PubMed] [Google Scholar]
- 19.Bett C., Joshi-Barr S., Lucero M., Trejo M., Liberski P., Kelly J. W., Masliah E., Sigurdson C. J., Biochemical properties of highly neuroinvasive prion strains. PLOS Pathog. 8, e1002522 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Aguzzi A., De Cecco E., Shifts and drifts in prion science. Science 370, 32–34 (2020). [DOI] [PubMed] [Google Scholar]
- 21.Zahn R., Liu A., Lührs T., Riek R., von Schroetter C., López García F., Billeter M., Calzolai L., Wider G., Wüthrich K., NMR solution structure of the human prion protein. Proc. Natl. Acad. Sci. U.S.A. 97, 145–150 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Watts J. C., Giles K., Bourkas M. E. C., Patel S., Oehler A., Gavidia M., Bhardwaj S., Lee J., Prusiner S. B., Towards authentic transgenic mouse models of heritable PrP prion diseases. Acta Neuropathol. 132, 593–610 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Asante E. A., Linehan J. M., Tomlinson A., Jakubcova T., Hamdan S., Grimshaw A., Smidak M., Jeelani A., Nihat A., Mead S., Brandner S., Wadsworth J. D. F., Collinge J., Spontaneous generation of prions and transmissible PrP amyloid in a humanised transgenic mouse model of A117V GSS. PLOS Biol. 18, e3000725 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Spagnolli G., Rigoli M., Orioli S., Sevillano A. M., Faccioli P., Wille H., Biasini E., Requena J. R., Full atomistic model of prion structure and conversion. PLOS Pathog. 15, e1007864 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25.Wille H., Bian W., McDonald M., Kendall A., Colby D. W., Bloch L., Ollesch J., Borovinskiy A. L., Cohen F. E., Prusiner S. B., Stubbs G., Natural and synthetic prion structure from X-ray fiber diffraction. Proc. Natl. Acad. Sci. U.S.A. 106, 16990–16995 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Smirnovas V., Baron G. S., Offerdahl D. K., Raymond G. J., Caughey B., Surewicz W. K., Structural organization of brain-derived mammalian prions examined by hydrogen-deuterium exchange. Nat. Struct. Mol. Biol. 18, 504–506 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Govaerts C., Wille H., Prusiner S. B., Cohen F. E., Evidence for assembly of prions with left-handed β-helices into trimers. Proc. Natl. Acad. Sci. U.S.A. 101, 8342–8347 (2004). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Vázquez-Fernández E., Vos M. R., Afanasyev P., Cebey L., Sevillano A. M., Vidal E., Rosa I., Renault L., Ramos A., Peters P. J., Jesús Fernández J., van Heel M., Young H. S., Requena J. R., Wille H., The structural architecture of an infectious mammalian prion using electron cryomicroscopy. PLOS Pathog. 12, e1005835 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Lu X., Wintrode P. L., Surewicz W. K., β-Sheet core of human prion protein amyloid fibrils as determined by hydrogen/deuterium exchange. Proc. Natl. Acad. Sci. U.S.A. 104, 1510–1515 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Cobb N. J., Sönnichsen F. D., Mchaourab H., Surewicz W. K., Molecular architecture of human prion protein amyloid: A parallel, in-register β-structure. Proc. Natl. Acad. Sci. U.S.A. 104, 18946–18951 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Terry C., Harniman R. L., Sells J., Wenborn A., Joiner S., Saibil H. R., Miles M. J., Collinge J., Wadsworth J. D. F., Structural features distinguishing infectious ex vivo mammalian prions from non-infectious fibrillar assemblies generated in vitro. Sci. Rep. 9, 376 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Glynn C., Sawaya M. R., Ge P., Gallagher-Jones M., Short C. W., Bowman R., Apostol M., Zhou Z. H., Eisenberg D. S., Rodriguez J. A., Cryo-EM structure of a human prion fibril with a hydrophobic, protease-resistant core. Nat. Struct. Mol. Biol. 27, 417–423 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33.Wang L. Q., Zhao K., Yuan H. Y., Wang Q., Guan Z., Tao J., Li X. N., Sun Y., Yi C. W., Chen J., Li D., Zhang D., Yin P., Liu C., Liang Y., Cryo-EM structure of an amyloid fibril formed by full-length human prion protein. Nat. Struct. Mol. Biol. 27, 598–602 (2020). [DOI] [PubMed] [Google Scholar]
- 34.A. Kraus, F. Hoyt, C. L. Schwartz, B. Hansen, A. G. Hughson, E. Artikis, B. Caughey, Structure of an infectious mammalian prion. bioRxiv [Preprint]. 2021. 10.1101/2021.02.14.431014. [DOI] [PubMed]
- 35.Peoc’h K., Manivet P., Beaudry P., Attane F., Besson G., Hannequin D., Delasnerie-Lauprêtre N., Laplanche J. L., Identification of three novel mutations (E196K, V203I, E211Q) in the prion protein gene (PRNP) in inherited prion diseases with Creutzfeldt-Jakob disease phenotype. Hum. Mutat. 15, 482 (2000). [DOI] [PubMed] [Google Scholar]
- 36.Schelzke G., Eigenbrod S., Romero C., Varges D., Breithaupt M., Taratuto A. L., Kretzschmar H. A., Zerr I., Genetic prion disease with codon 196 PRNP mutation: Clinical and pathological findings. Neurobiol. Aging 32, 756.e1–756.e9 (2011). [DOI] [PubMed] [Google Scholar]
- 37.Krasnianski A., Heinemann U., Ponto C., Kortt J., Kallenberg K., Varges D., Schulz-Schaeffer W. J., Kretzschmar H. A., Zerr I., Clinical findings and diagnosis in genetic prion diseases in Germany. Eur. J. Epidemiol. 31, 187–196 (2016). [DOI] [PubMed] [Google Scholar]
- 38.Hadži S., Ondračka A., Jerala R., Hafner-Bratkovič I., Pathological mutations H187R and E196K facilitate subdomain separation and prion protein conversion by destabilization of the native structure. FASEB J. 29, 882–893 (2015). [DOI] [PubMed] [Google Scholar]
- 39.Zhou Z., Yan X., Pan K., Chen J., Xie Z. S., Xiao G. F., Yang F. Q., Liang Y., Fibril formation of the rabbit/human/bovine prion proteins. Biophys. J. 101, 1483–1492 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Torrent J., Martin D., Noinville S., Yin Y., Doumic M., Moudjou M., Béringue V., Rezaei H., Pressure reveals unique conformational features in prion protein fibril diversity. Sci. Rep. 9, 2802 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Bocharova O. V., Breydo L., Salnikov V. V., Baskakov I. V., Copper(II) inhibits in vitro conversion of prion protein into amyloid fibrils. Biochemistry 44, 6776–6787 (2005). [DOI] [PubMed] [Google Scholar]
- 42.Terry C., Wenborn A., Gros N., Sells J., Joiner S., Hosszu L. L. P., Tattum M. H., Panico S., Clare D. K., Collinge J., Saibil H. R., Wadsworth J. D. F., Ex vivo mammalian prions are formed of paired double helical prion protein fibrils. Open Biol. 6, 160035 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.Scheres S. H. W., Amyloid structure determination in RELION-3.1. Acta Crystallogr. D Struct. Biol. 76, 94–101 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Boyer D. R., Li B., Sun C., Fan W., Sawaya M. R., Jiang L., Eisenberg D. S., Structures of fibrils formed by α-synuclein hereditary disease mutant H50Q reveal new polymorphs. Nat. Struct. Mol. Biol. 26, 1044–1052 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Zhang W., Tarutani A., Newell K. L., Murzin A. G., Matsubara T., Falcon B., Vidal R., Garringer H. J., Shi Y., Ikeuchi T., Murayama S., Ghetti B., Hasegawa M., Goedert M., Scheres S. H. W., Novel Tau filament fold in corticobasal degeneration. Nature 580, 283–287 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 46.Gallardo R., Iadanza M. G., Xu Y., Heath G. R., Foster R., Radford S. E., Ranson N. A., Fibril structures of diabetes-related amylin variants reveal a basis for surface-templated assembly. Nat. Struct. Mol. Biol. 27, 1048–1056 (2020). [DOI] [PubMed] [Google Scholar]
- 47.Cobb N. J., Apostol M. I., Chen S., Smirnovas V., Surewicz W. K., Conformational stability of mammalian prion protein amyloid fibrils is dictated by a packing polymorphism within the core region. J. Biol. Chem. 289, 2643–2650 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Safar J. G., Xiao X., Kabir M. E., Chen S., Kim C., Haldiman T., Cohen Y., Chen W., Cohen M. L., Surewicz W. K., Structural determinants of phenotypic diversity and replication rate of human prions. PLOS Pathog. 11, e1004832 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Guest W. C., Cashman N. R., Plotkin S. S., Electrostatics in the stability and misfolding of the prion protein: Salt bridges, self energy, and solvation. Biochem. Cell Biol. 88, 371–381 (2010). [DOI] [PubMed] [Google Scholar]
- 50.Donald J. E., Kulp D. W., DeGrado W. F., Salt bridges: Geometrically specific, designable interactions. Proteins 79, 898–915 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51.Spagnolli G., Rigoli M., Inverardi G. N., Codeseira Y. B., Biasini E., Requena J. R., Modeling PrPSc generation through deformed templating. Front. Bioeng. Biotechnol. 8, 590501 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52.Artikis E., Roy A., Verli H., Cordeiro Y., Caughey B., Accommodation of in-register N-linked glycans on prion protein amyloid cores. ACS Chem. Neurosci. 11, 4092–4097 (2020). [DOI] [PubMed] [Google Scholar]
- 53.Kang H. E., Bian J., Kane S. J., Kim S., Selwyn V., Crowell J., Bartz J. C., Telling G. C., Incomplete glycosylation during prion infection unmasks a prion protein epitope that facilitates prion detection and strain discrimination. J. Biol. Chem. 295, 10420–10433 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Sevillano A. M., Aguilar-Calvo P., Kurt T. D., Lawrence J. A., Soldau K., Nam T. H., Schumann T., Pizzo D. P., Nyström S., Choudhury B., Altmeppen H., Esko J. D., Glatzel M., Nilsson K. P. R., Sigurdson C. J., Prion protein glycans reduce intracerebral fibril formation and spongiosis in prion disease. J. Clin. Invest. 130, 1350–1362 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 55.Zheng S. Q., Palovcak E., Armache J. P., Verba K. A., Cheng Y., Agard D. A., MotionCor2: Anisotropic correction of beam-induced motion for improved cryo-electron microscopy. Nat. Methods 14, 331–332 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 56.Rohou A., Grigorieff N., CTFFIND4: Fast and accurate defocus estimation from electron micrographs. J. Struct. Biol. 192, 216–221 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Emsley P., Lohkamp B., Scott W. G., Cowtan K., Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486–501 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58.Adams P. D., Afonine P. V., Bunkóczi G., Chen V. B., Davis I. W., Echols N., Headd J. J., Hung L. W., Kapral G. J., Grosse-Kunstleve R. W., McCoy A. J., Moriarty N. W., Oeffner R., Read R. J., Richardson D. C., Richardson J. S., Terwilliger T. C., Zwart P. H., PHENIX: A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213–221 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 59.Chattopadhyay M., Durazo A., Sohn S. H., Strong C. D., Gralla E. B., Whitelegge J. P., Valentine J. S., Initiation and elongation in fibrillation of ALS-linked superoxide dismutase. Proc. Natl. Acad. Sci. U.S.A. 105, 18663–18668 (2008). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Mo Z. Y., Zhu Y. Z., Zhu H. L., Fan J. B., Chen J., Liang Y., Low micromolar zinc accelerates the fibrillization of human Tau via bridging of Cys-291 and Cys-322. J. Biol. Chem. 284, 34648–34657 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.